Amiodarone induced liver cirrhosis. Report of two cases

Journal of Gastrointestinal and Liver Diseases

Volumn 18, Issue 2, 2009, Pages 233-235

  Atiq, Muslim ^a   Davis, Jeremy C ^a   Lamps, Laura W ^a   Beland, Susan S ^a   Rose, James E ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLIPIZIDE; SIMVASTATIN; ANTIARRHYTHMIC AGENT;

ABDOMINAL TENDERNESS; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; CHRONIC KIDNEY DISEASE; CONFUSION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOPPLER ECHOGRAPHY; FATIGUE; FEMALE; FLAPPING TREMOR; HUMAN; HYPERTENSION; LIVER BIOPSY; LIVER CIRRHOSIS; LOW DRUG DOSE; MALE; NONALCOHOLIC FATTY LIVER; PROTHROMBIN TIME; SPLENOMEGALY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FATALITY; LIVER; PATHOLOGY;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; FATAL OUTCOME; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE;

EID: 70149088655     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9: 679-685. (Pubitemid 19123513)
2. Puli SR, Fraley MA, Puli V, Kuperman AB, Alpert MA. Hepatic cirrhosis caused by low-dose oral amiodarone therapy. Am J Med Sci 2005; 330: 257-261. (Pubitemid 41689456)
3. Breuer HW, Bossek W, Haferland C, Schmidt M, Neumann H, Gruszka J. Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int J Clin Pharmacol Ther 1998; 36: 350-352. (Pubitemid 28271556)
4. Singhal A, Ghosh P, Khan SA. Low dose amiodarone causing pseudoalcoholic cirrhosis. Age Ageing 2003; 32: 224-225. (Pubitemid 36372432)
5. Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984; 311: 167-172. (Pubitemid 14092908)
6. Guigui B, Perrot S, Berry JP, et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 1988; 8: 1063-1068. (Pubitemid 18236604)
7. Itostetler K, Reasor M, Frazee BW. Mechanisms of amiodarone toxicity: inhibition of phospholipase A. Circulation 1984;79 (Suppl II):240.
8. Heath MF, Costa-Jussa FR, Jacobs JM, et al. The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br J Exp Pathol 1985;66:391-397
9. Lewis JH, Mullick F, Ishak KG, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21: 59-67. (Pubitemid 20042406)
10. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003; 38: 133-140 (Pubitemid 36775804)
11. Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 2007; 46: 985-996. (Pubitemid 350136908)
12. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30: 121-138 (Pubitemid 38715168)
13. Fromenty B, Fisch C, Labbe G, et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol ExpTher 1990; 255: 1371-1376
14. Çoban S, Köklü S, Sencer H, Ekiz F, Ormeci N. Low dose amiodarone associated cirrhosis. J Gastroenterol Hepatol 2007; 22: 140-141.
15. Oikawa H, Maesawa C, Sato R, et al. Liver cirrhosis induced by longterm administration of a daily low dose of amiodarone: a case report. World J Gastroenterol 2005; 11: 5394-5397. (Pubitemid 41410315)
16. Jeyamalar R, Pathmanathan R, Wong D, Kannan P. Hepatotoxicity of amiodarone. Ann Acad Med Singapore 1992; 21: 838-840.
17. Tordjman K, Katz I, Bursztyn M, Rosenthal T. Amiodarone and the liver. Ann Intern Med 1985; 102: 411-412.
18. Rinder HM, Love JC, Wexler R. Amiodarone hepatotoxicity. N Engl J Med 1986; 314: 318-319.
19. Flaharty KK, Chase SL, Yaghsezian HM, Rubin R. Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy 1989; 9: 39-44.
20. Pollak PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther 2004; 75: 342-351.